Latest revenue
—
as of —
Latest net income
—
as of —
Net margin
—
as of —
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $2.45B
- Enterprise value
- $2.45B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $26.25
- 52-wk low
- $6.34
- Beta
- —
- Shares out
- 109.1M
5-year trend
What this company does
Item 1. Business. Overview We are a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. We are developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes including DT120 (previously referred to as MM120), and DT402 (previously referred to as MM402), our…
AI summary unavailable — showing raw filing excerpt
Generated from DFTX's filing dated 2026-02-26
Key risks
Item 1A. Risk Factors. The following information sets forth risk factors that could cause our actual results to differ materially from those contained in forward-looking statements we have made in this Annual Report and those we may make from time to time. You should carefully consider the risks described below, as well as the other information in this Annual Report, including our financial statements and related notes and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and in our other public filings in evaluating our business. The occurrence of any of the events or developments described below could harm our business, financial…
AI summary unavailable — showing raw filing excerpt
Generated from DFTX's filing dated 2026-02-26
Profitability
Operating margin
-2012.6%
54.6%Net margin
-2052.6%
46.0%Return on equity
-55.3%
22.9%Return on assets
-41.8%
16.1%Leverage
Debt / equity
0.32×
29.0%Long-term debt / equity
0.12×
34.9%Debt / assets
24.5%
21.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-77.1M | -230.2% | — |
Q4 2025 2025-12-31 | — | — | $-50.4M | -45.2% | — |
Q3 2025 2025-09-30 | — | — | $-67.3M | -391.6% | — |
Q2 2025 2025-06-30 | — | — | $-42.7M | -630.2% | — |
Q1 2025 2025-03-31 | — | — | $-23.3M | +57.1% | — |
Q4 2024 2024-12-31 | — | — | $-34.7M | — | — |
Q3 2024 2024-09-30 | — | — | $-13.7M | +23.7% | — |
Q2 2024 2024-06-30 | — | — | $-5.9M | +79.9% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Medicinal Chemicals & Botanical Products · SIC 2833
Your notes
Keep private notes on DFTX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$2.1M
Net activity
−$2.1M
Distinct insiders
3
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns DFTX
Institutional value
$353.8M
Total shares held
18.8M
Distinct holders
134
+126 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 8.5M | $160.3M | — | New |
| 2 | Candriam S.C.A. | 1.3M | $24.4M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 1.1M | $20.7M | — | New |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 872.7K | $16.5M | — | New |
| 5 | Bank of New York Mellon Corp | 752.9K | $14.2M | — | New |
| 6 | Nuveen, LLC | 698.1K | $13.2M | — | New |
| 7 | VANGUARD FIDUCIARY TRUST CO | 575.9K | $10.9M | — | New |
| 8 | Ensign Peak Advisors, Inc | 546.8K | $10.3M | +284.8K (+108.7%) | Added |
| 9 | UBS Group AG | 494.0K | $9.3M | — | New |
| 10 | DEUTSCHE BANK AG\ | 411.8K | $7.8M | — | New |
| 11 | BIT Capital GmbH | 277.5K | $5.2M | — | New |
| 12 | JANE STREET GROUP, LLC | 260.2K | $4.9M | — | New |
| 13 | JPMORGAN CHASE & CO | 264.5K | $4.6M | — | New |
| 14 | ROYCE & ASSOCIATES LP | 234.1K | $4.4M | — | New |
| 15 | SEVEN GRAND MANAGERS, LLC | 225.0K | $4.3M | — | New |
| 16 | Swiss National Bank | 158.4K | $3.0M | — | New |
| 17 | RHUMBLINE ADVISERS | 120.0K | $2.3M | — | New |
| 18 | Russell Investments Group, Ltd. | 119.5K | $2.3M | — | New |
| 19 | AdvisorShares Investments LLC | 91.3K | $1.7M | — | New |
| 20 | Invesco Ltd. | 88.1K | $1.7M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once DFTX's latest filing finishes processing.